Britannia Pharmaceuticals Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients with Advanced Parkinson's Disease
Active, not recruiting
- Conditions
- Advanced Parkinson Disease
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05043103
- Locations
- 🇦🇹
Universitätsklinik für Neurologie, Medizinische Universität Graz, Graz, Austria
🇦🇹Abteilung für Neurologische Rehabilitation, Gailtal-Klinik, Hermagor, Austria
🇦🇹Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Innsbruck, Austria
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT02006121
- Locations
- 🇦🇹
Medizinische Universität Graz / Univ. Klinik für Neurologie, Graz, Austria
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Donauspital / SMZ-Ost, Abteilung für Neurologie, Sekretariat (Stock 1, Ebene 4), Vienna, Austria
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Phase 2
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT00346827
News
No news found